Cargando…

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion

In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veríssimo, Monica Pinheiro de Almeida, Loggetto, Sandra Regina, Fabron Junior, Antonio, Baldanzi, Giorgio Roberto, Hamerschlak, Nelson, Fernandes, Juliano Lara, Araujo, Aderson da Silva, Lobo, Clarisse Lopes de Castro, Fertrin, Kleber Yotsumoto, Berdoukas, Vasilios Antonios, Galanello, Renzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Hematologia e Hemoterapia 2013
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905826/ https://www.ncbi.nlm.nih.gov/pubmed/24478610 http://dx.doi.org/10.5581/1516-8484.20130106

Ejemplares similares

Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study
por: Chapchap, Eduardo Cerello, et al.
Publicado: (2023)

Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy
por: Farmaki, Kallistheni, et al.
Publicado: (2008)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective
por: Galanello, Renzo
Publicado: (2007)

Beta-thalassemia
por: Galanello, Renzo, et al.
Publicado: (2010)

Pregnancy in sickle cell disease – do we know what to expect?()
por: Fertrin, Kleber Yotsumoto
Publicado: (2014)

It is never too late to rethink serum folate()
por: Fertrin, Kleber Yotsumoto
Publicado: (2018)

Successful chelation in beta-thalassemia major in the 21(st) century
por: Fragodimitri, Christina, et al.
Publicado: (2023)

Recent advances in β-thalassemias
por: Cao, Antonio, et al.
Publicado: (2011)

Guidelines on Beta-thalassemia major – regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associação Médica Brasileira – 2016
por: Langhi, Dante, et al.
Publicado: (2016)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
por: Tanner, Mark A, et al.
Publicado: (2008)

Sickling Cells, Cyclic Nucleotides, and Protein Kinases: The Pathophysiology of Urogenital Disorders in Sickle Cell Anemia
por: Claudino, Mário Angelo, et al.
Publicado: (2012)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: Our experience
por: Jethani, Jitendra, et al.
Publicado: (2010)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

The heart in transfusion dependent homozygous thalassaemia today – prediction, prevention and management
por: Aessopos, Athanassios, et al.
Publicado: (2008)

Comparison of echocardiographic (US) volumetry with cardiac magnetic resonance (CMR) imaging in transfusion dependent thalassemia major (TM)
por: Giakoumis, Anastasios, et al.
Publicado: (2007)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Prevention of Cardiomyopathy in Transfusion-Dependent Homozygous Thalassaemia Today and the Role of Cardiac Magnetic Resonance Imaging
por: Aessopos, Athanassios, et al.
Publicado: (2009)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
por: Saliba, Antoine N, et al.
Publicado: (2015)

Non-transfusion dependent hemoglobin E/β thalassemia had high prevalence of vitamin D deficiency than more severe patients who received regular blood transfusion and iron chelation therapy
por: Nakavachara, Pairunyar, et al.
Publicado: (2013)

Cardio-protective effect of regular transfusion in children with non-transfusion dependent thalassemia (NTDT): A cohort study
por: Al Senaidi, Khalfan, et al.
Publicado: (2022)

P1454: CLINICAL DETERMINANTS OF CARDIAC IRON IN REGULARLY TRANSFUSED THALASSEMIA INTERMEDIA PATIENTS
por: Meloni, Antonella, et al.
Publicado: (2023)

Thalassemia Major in Adults: Short Stature, Hyperpigmentation, Inadequate Chelation, and Transfusion-Transmitted Infections are Key Features
por: Prakash, Anupam, et al.
Publicado: (2012)

The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study
por: Berdoukas, Vasilios, et al.
Publicado: (2009)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major
por: Ejaz, Muzamil Shabana, et al.
Publicado: (2015)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
por: Origa, Raffaella, et al.
Publicado: (2022)

Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit
por: Ladis, Vassilios, et al.
Publicado: (2010)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia
por: Goulas, Vasilis, et al.
Publicado: (2012)

Beliefs about chelation among thalassemia patients
por: Trachtenberg, Felicia L, et al.
Publicado: (2012)

A Multicenter ICET-A Study on Age at Menarche and Menstrual Cycles in Patients with Transfusion-Dependent Thalassemia (TDT) who Started Early Chelation Therapy with Different Chelating Agents
por: Di Maio, Salvatore, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vuqsrg3udscf1q3tvft70irj44